菲立磁增强MR淋巴造影检测泌尿生殖系统恶性肿瘤转移性淋巴结的前瞻性研究
这项2期单中心前瞻性研究纳入39例前列腺癌、膀胱癌和肾癌患者,静脉注射菲立磁后24和48小时行MR淋巴造影,基于淋巴结水平的敏感度为98.0%、特异度为64.4%;转移性淋巴结在24小时较48小时标准化信号强度下降百分比更高(p=0.023),非转移性淋巴结两个时间点相似(p=0.260)。
要点
- 菲立磁增强MR淋巴造影检测泌尿生殖系统肿瘤转移性淋巴结的敏感度为98.0%,特异度为64.4%。
- 转移性淋巴结注射后24小时标准化信号强度下降百分比显著高于48小时(p=0.023)。
- 敏感度和特异度不随淋巴结大小变化。
核心结论
- 菲立磁增强MR淋巴造影检测泌尿生殖系统恶性肿瘤转移性淋巴结敏感度高,且不依赖淋巴结大小。
- 良性与恶性淋巴结的信号强度差异在注射后24和48小时似乎相似,提示注射后1或2天内可安全成像。
- 菲立磁增强MR淋巴造影在无可用靶向PET显像剂的情况下可能有用,但铁过载和可重复性问题仍是顾虑。
研究设计与样本
- 2期单中心前瞻性研究,纳入确诊前列腺癌(第1组)、膀胱癌(第2组)和肾癌(第3组)且疑有淋巴结受累证据的患者。
- 共39例患者(第1组n=30,第2组n=6,第3组n=3),中位年龄65岁,评估145枚淋巴结(转移性n=100,良性n=45)。
- 静脉注射菲立磁7.5 mg Fe/kg后24和48小时行菲立磁增强MR淋巴造影。
- 回顾性定量分析采用线性混合效应模型估计标准化信号强度自基线的百分比变化,固定效应自变量为时间(24 vs 48小时)、疾病状态及时间与疾病状态交互作用。
- 亚组间标准化信号强度差异通过固定效应对比估计并用Wald检验。
关键影像表现/征象
- 转移性淋巴结在注射后24小时标准化信号强度下降百分比显著高于48小时(p=0.023)。
- 非转移性淋巴结在24和48小时的标准化信号强度值相似(p=0.260)。
诊断标准与关键数值
- 基于淋巴结水平的菲立磁增强MR淋巴造影敏感度为98.0%、特异度为64.4%、阳性预测值为86.0%、阴性预测值为93.5%。
- 菲立磁增强MR淋巴造影的敏感度和特异度不随淋巴结大小变化。
临床应用与阅片要点
- 菲立磁增强MR淋巴造影在无可用靶向PET显像剂的情况下可能有用。
- 注射后24和48小时良性及恶性淋巴结信号强度差异似乎相似,提示注射后1或2天内可安全成像。
- 铁过载和菲立磁增强MR淋巴造影的可重复性问题仍是该方法的顾虑。
局限性
- 铁过载和菲立磁增强MR淋巴造影的可重复性问题仍是该方法的顾虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The objective of our study was to evaluate the utility of ferumoxytol-enhanced MR lymphography (MRL) in detection of metastatic lymph nodes (LNs) in patients with prostate, bladder, and kidney cancer. SUBJECTS AND METHODS. This phase 2 single-institution study enrolled patients with confirmed prostate (arm 1), bladder (arm 2), and kidney (arm 3) cancer and evidence of suspected LN involvement. Participants underwent ferumoxytol-enhanced MRL 24 and 48 hours after IV injection of 7.5 mg Fe/kg of ferumoxytol. A retrospective quantitative analysis was performed to determine the optimal timing for ferumoxytol-enhanced MRL using percentage change in normalized signal intensity (SI) from baseline to 24 and 48 hours after injection, which were estimated using the linear mixed-effects model in which time (24 vs 48 hours), diseases status, and time and disease status interaction were the fixed-effects independent variables. Differences in normalized SI values between subgroups of lesions were estimated by forming fixed-effects contrasts and tested by the Wald test. RESULTS. Thirty-nine patients (n = 30, arm 1; n = 6, arm 2; n = 3, arm 3) (median age, 65 years) with 145 LNs (metastatic, n = 100; benign, n = 45) were included. LN-based sensitivity, specificity, positive predictive value, and negative predictive value of ferumoxytol-enhanced MRL was 98.0%, 64.4%, 86.0%, and 93.5%, respectively. Sensitivity and specificity of ferumoxytol-enhanced MRL did not vary by LN size. Metastatic LNs showed a significantly higher percentage decrease of normalized SI on MRL at 24 hours after ferumoxytol injection than at 48 hours after ferumoxytol injection (p = 0.023), whereas the normalized SI values for nonmetastatic LNs were similar at both imaging time points (p = 0.260). CONCLUSION. Ferumoxytol-enhanced MRL shows high sensitivity in the detection of metastatic LNs in genitourinary cancers independent of LN size. The SI difference between benign and malignant LNs on ferumoxytol-enhanced MRL appears similar 24 and 48 hours after ferumoxytol injection, suggesting that imaging can be performed safely within 1 or 2 days of injection. Although ferumoxytol-enhanced MRL can be useful in settings without an available targeted PET agent, issues of iron overload and repeatability of ferumoxytol-enhanced MRL remain concerns for this method.
引用
- Turkbey B, Czarniecki M, Shih JH, et al. Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. AJR Am J Roentgenol. 2019. PMID: 31613660. doi:10.2214/AJR.19.21264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。